Publications by authors named "M LAIRD"

In dermatology, the art and skill of morphologic assessment is key to generating logical differential diagnoses and understanding disease pathogenesis. Dr. Irwin M.

View Article and Find Full Text PDF

Macrophages are pivotal in driving breast tumor development, progression, and resistance to treatment, particularly in estrogen receptor-positive (ER+) tumors, where they infiltrate the tumor microenvironment (TME) influenced by cancer cell-secreted factors. By analyzing single-cell RNA sequencing data from 25 ER+ tumors, we elucidated interactions between cancer cells and macrophages, correlating macrophage density with epithelial cancer cell density. We identified that S100A11, a previously unexplored factor in macrophage-cancer crosstalk, predicts high macrophage density and poor outcomes in ER+ tumors.

View Article and Find Full Text PDF

Introduction: Fibroblasts, an abundant cell type in the breast tumor microenvironment, interact with cancer cells and orchestrate tumor progression and drug resistance. However, the mechanisms by which fibroblast-derived factors impact drug sensitivity remain poorly understood. Here, we develop rational combination therapies that are informed by proteomic profiling to overcome fibroblast-mediated therapeutic resistance in HER2+ breast cancer cells.

View Article and Find Full Text PDF
Article Synopsis
  • X chromosome inactivation (XCI) is an epigenetic phenomenon where one X chromosome in females is silenced, differing between eutherian (random silencing) and marsupial mammals (always paternal silencing).
  • In eutherians, the inactive X shows high DNA methylation at key sites, while marsupials have lower methylation levels on the paternal X.
  • The study focused on the tammar wallaby's X chromosome during sperm development, finding that the paternal X has a DNA methylation profile similar to the inactive X in female tissues, suggesting it may serve as an imprint for paternal XCI in marsupials.
View Article and Find Full Text PDF

The success of chimeric antigen receptor (CAR) T cells in blood cancers has intensified efforts to develop CAR T therapies for solid cancers. In the solid tumor microenvironment, CAR T cell trafficking and suppression of cytotoxic killing represent limiting factors for therapeutic efficacy. Here, we present a microwell platform to study CAR T cell interactions with 3D breast tumor spheroids and determine predictors of anti-tumor CAR T cell function.

View Article and Find Full Text PDF